Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Minerva Urology and Nephrology 2021 June;73(3) > Minerva Urology and Nephrology 2021 June;73(3):349-56



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo


ORIGINAL ARTICLE   Free accessfree

Minerva Urology and Nephrology 2021 June;73(3):349-56

DOI: 10.23736/S2724-6051.20.03646-2


lingua: Inglese

Incidence, predictive factors and survival outcomes of incidental prostate cancer in patients who underwent radical cystectomy for bladder cancer

Francesco CLAPS 1, Nicola PAVAN 1 , Paolo UMARI 2, Michele RIZZO 1, Fabio BARBONE 3, Manuela GIANGRECO 4, Giovanni LIGUORI 1, Carmen M. MIR 5, Rossana BUSSANI 6, Carlo TROMBETTA 1

1 Urology Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy; 2 Department of Urology, A. Avogadro University of Eastern Piedmont, Novara, Italy; 3 IRCCS Burlo Garofalo Children’s Hospital, University of Trieste, Trieste, Italy; 4 Institute of Hygiene and Clinical Epidemiology, University of Udine, Udine, Italy; 5 Department of Urology, Valencian Oncology Institute and Foundation (IVO), Valencia, Spain; 6 Institute of Pathological Anatomy, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy

BACKGROUND: The aim of this study was to analyze the incidence, preoperative findings, pathological features and prognosis in patients with incidental prostate cancer (iPCa) detected at radical cystectomy (RC) for bladder cancer (BCa).
METHODS: We retrospectively reviewed data of patients who underwent RC for BCa at our Institution between January 2005 and March 2018. Data regarding patient’s history, preoperative digital rectal examination (DRE), total serum PSA level were collected from the chart review. Univariable and multivariable Cox regression models addressed the association of iPCa with recurrence-free survival (RFS) and overall survival (OS).
RESULTS: We obtained a final study cohort of 177 patients. Median age was 69 years (IQR 42-89) and 80(45.2%) patients had iPCa. Patients with iPCa had higher age, preoperative PSA levels and a significant rate of suspicious DRE (all P<0.05). Four patients had BCR during a median follow-up of 28 months (IQR 6-159) and none died for prostate cancer. In multivariable analyses adjusted for age, bladder cancer BCa pT and pN stage and LVI the ten-years RFS and OS rates were not impacted by iPCa regardless of whether it is a clinically significant cancer or not (HR=1.25, 95% CI: 0.65-2.38, P=0.51 vs. HR=1.37, 95% CI: 0.71-2.64, P=0.35) (HR=1.04, 95% CI: 0.53-1.86, P=0.89 vs. HR=1.20, 95% CI: 0.22-6.72, P=0.83).
CONCLUSIONS: iPCa is quite common in our study group and most of cases are organ-confined and well differentiated. Regardless of clinical relevance, iPCa does not have an impact on survival outcomes as BCa is driving the prognosis of these patients.

KEY WORDS: Prostatic neoplasms; Cystectomy; Urinary bladder neoplasms; Prostate-specific antigen; Survival

inizio pagina